INMB news

INmune Bio secured a Master Services Agreement with Uniphar to facilitate international access and distribution of its stem cell therapy Ebstrocel, prioritizing named-patient programs in Europe and MENA to boost commercial scalability.

Inmune Bio strengthens commercialization and strategy capabilities with the appointment of two executives from Sanofi and biotech leadership roles ahead of Ebstrocel's potential launch.

Inmune Bio Inc. has amended and restated its 2021 Stock Incentive Plan to provide equity awards to executives, employees, advisors and board members. The plan modification enables the company to continue incentivizing talent retention and aligning employee interests with long-term shareholder value …

INmune Bio reported Phase 2 MINDFuL trial results showing XPro1595 demonstrated significant treatment effects on advanced white matter MRI biomarkers (p=0.0028), with stronger efficacy in inflammation-enriched patients. The findings support the company's precision-medicine approach and align with it…